Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Submitted by
admin
on August 30, 2018 - 10:14am
Source:
CP Wire
News Tags:
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Headline:
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
snippet:
Domagrozumab Ph II study did not meet primary endpoint
Pfizer is also developing a gene therapy, PF-06939926, for DMD
PF-06939926 has orphan status in the US and Europe
Do Not Allow Advertisers to Use My Personal information